Cellura

Cellura is a pioneering French biotech firm headquartered in Marseille, emerging from a collaboration between CNRS‑IRPHE (Aix‑Marseille Université) researchers and industry innovators. Its core mission is to revolutionize the cultivation of shear-sensitive cells—ranging from human stem cells and natural killer cells to delicate microalgae like dinoflagellates—by harnessing a unique geoinspired mixing technology that mimics Earth’s gentle precessional motion.

At the heart of Cellura’s offering is the SoftXS bioreactor: a bladeless, scalable suspension culture system that delivers precise control over shear forces while enabling exceptional mass transfer and ease of scale-up . This breakthrough allows unprecedented 3D expansion of fragile cell types that traditional stirred-tank reactors struggle to handle—paving the way for cost-effective bioproduction in both research and clinical contexts.

Cellura envisions a future where advanced therapies for conditions like cancer, neurodegeneration, and diabetes become accessible and scalable. By addressing critical bottlenecks in cell manufacturing, the company aims to democratize cellular therapies and make them viable for real-world healthcare applications. 

Key highlights

• Innovation rooted in earth‑inspired engineering: Utilizes gentle, turbulence‑based mixing to preserve cell integrity .

• SoftXS platform: A versatile, scalable tool enabling expansion from lab to industrial volumes with tight shear control and high mass transfer.

• Impactful cell models: Proven efficacy with iPSCs (up to 100‑fold expansion), functional NK cells, and high‑yield dinoflagellates, supporting both therapeutic and pharmaceuticals pipelines.

• Vision-driven: Aiming to bring scalable, affordable biomanufacturing into mainstream R&D and clinical manufacturing.

In essence, Cellura offers a groundbreaking pathway for scalable, gentle cell production—unlocking possibilities in regenerative medicine, immunotherapy, and bioactive compound discovery.

Website: https://cellura.io/